Inovio Pharmaceuticals, Inc.

Inovio Pharmaceuticals (INO) is a clinical‑stage biotechnology company developing DNA‑based vaccines and immunotherapies, using a proprietary electroporation delivery platform. Investors should know it is small‑cap and research‑driven: value is tied to clinical trial readouts, regulatory progress and partnerships rather than stable revenues. The company’s pipeline targets infectious diseases and oncology, and progress often comes in discrete, binary milestones that can cause sharp share‑price moves. As a small biopharma, Inovio may need to raise capital from time to time, which can dilute shareholders. Key considerations for investors include the stage and quality of clinical data, cash runway, partner relationships and the competitive landscape for vaccine and immunotherapy technologies. This summary is educational and not personalised advice — biotech investing carries elevated risk and potential volatility, and past developments are not a reliable guide to future results.